Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Open Access
- 19 May 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 75 (2) , 501-519
Abstract
Background: Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins. Objective: To compare hydromethylthionine treatment effects at two doses and to determine how drug exposure is related to treatment responseKeywords
This publication has 77 references indexed in Scilit:
- Gray matter atrophy rate as a marker of disease progression in ADNeurobiology of Aging, 2012
- Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivoAutophagy, 2012
- Mitochondrial pharmacology: Electron transport chain bypass as strategies to treat mitochondrial dysfunctionBioFactors, 2012
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Methylene blue inhibits function of the 5‐HT transporterBritish Journal of Pharmacology, 2011
- Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 yearNeurology, 2009
- Development of methodology for conducting clinical trials in frontotemporal lobar degenerationBrain, 2008
- Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical predictionBritish Journal of Pharmacology, 2007
- The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screeningInternational Journal of Geriatric Psychiatry, 2006
- Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and manJournal of Theoretical Biology, 1968